Surgical Oncologist / Professor of Surgery and Pharmacology
UC San Diego Health
Dr. Jason Sicklick is an NIH and FDA R01 funded investigator, Professor of Surgery and Adjunct Professor of Pharmacology, Executive Vice Chair of Research in the Department of Surgery, Associate Program Director of the General Surgery Residency at UC San Diego, and Leader of the Sarcoma Disease Team at the UC San Diego Moores Cancer Center. He is a board-certified general surgeon and surgical oncologist specializing in the treatment of complex retroperitoneal and abdominal sarcomas, including gastrointestinal stromal tumors (GIST), as well as hepatobiliary oncology. He received his medical degree from the UCLA School of Medicine, completed his general surgery residency at The Johns Hopkins Hospital, and completed a fellowship in surgical oncology at Memorial Sloan Kettering Cancer Center. He joined the UC San Diego Division of Surgical Oncology at Moores Cancer Center in 2010. Dr. Sicklick is an active member of the NCCN Soft Tissue Sarcoma/GIST Committee and the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). He also serves on the medical advisory board of The Life Raft Group, as well as chairs Study Section Panel B (Translational) of the Israel Cancer Research Fund (ICRF) and serves on their International Scientific Council. Dr. Sicklick is currently on the Editorial Boards of Journal of Gastrointestinal Surgery and Cancer, as well as previously served for Annals of Surgical Oncology and Journal of Surgical Research. He has published in prestigious journals such as Nature Medicine, Clinical Cancer Research, Oncogene, Lancet Oncology, JAMA Surgery, Annals of Surgery, Archives of Surgery, and Annals of Surgical Oncology. He is an active member of the numerous societies including the American Surgical Association, Society of Clinical Surgery, Halsted Society, Society for University Surgeons, Society of Surgical Oncology, American Society of Clinical Oncology, American Association for Cancer Research, Connective Tissue Oncology Society, and American College of Surgeons.